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Pre-clinical studies suggest that combined blockade of ETA
and AT1 receptors reduces end-organ injury to a greater extent
than either receptor antagonist alone. Towards this end, dual ET/
AngII receptor antagonists (DARAs) have been developed. The ﬁrst
DARA was reported by Bristol Myers Squibb in 2002 and was
based on the observation that ETA antagonists shared the same
biphenyl core as several AT1 receptor blockers. A series of these
biphenylsulfonamides were reported in 2003 and 2004 and found to
be orally active in several rat models of hypertension (AngII, DOCA
and SHR). Subsequent synthesis of a 2′-substituted N-3-isoxazolyl
biphenylsulfonamide led to a second generation DARA compound
with improved pharmacokinetics and enhanced ETA and AT1
receptor potency (Ki of 0.8 nM and 9.3 nM for human AT1 and ETA
receptors, respectively). Pharmacopeia acquired the license for the
DARA, renaming it PS433540. Based on several Phase I studies, they
conducted a single blind Phase IIa study in patients with mild
to moderate hypertension (NCT00522925) with a primary endpoint
of change in 24-hr systolic BP after 4 weeks of placebo (N = 28),
200 mg (N = 38) or 500 mg (N = 36) daily of drug. The results,
reported in 2008, demonstrated no change with placebo, a 12/
9 mm Hg or 15/10 mm Hg drop in SBP/DBP with 200 mg or 500 mg
of drug, respectively. There were no signiﬁcant adverse events. Ligand
Pharmaceuticals acquire Pharmacopeia and conducted a Phase IIb trial
in a similar group of hypertensive patients (NCT00635232). Patients
were treated daily with 200 mg (N = 55), 400 mg (N = 48) or
800 mg (N = 20) PS433540, placebo (N = 39), or 300 mg irbesartan
(N = 44). The primary endpoint was change in ofﬁce SBP after
12 weeks. The SBP/DBP decreased by 1.8/0.2, 10.7/7.1, 13.2/7.2, 14.2/
9.2 and 23.4/14.3 in the placebo, irbesartan, 200, 400 and 800 mg
PS433540 groups, respectively. Peripheral edema (all mild to
moderate) was noted in 2–3% of patients treated with irbesartan,
placebo or 200 mg PS433540, while it occurred in 6.9 and 10.7% of
patients receiving 400 and 800 mg PS433540, respectively. More
patients on the highest DARA dose had dizziness, ﬂushing and
GI symptoms. Ligand licensed the DARA to Retrophin in 2012 who
are currently planning a Phase II trial (NCT01613118) with 4
different doses of the now renamed RE-021, as well as the active
comparator irbesartan, in 72 patients, aged 8–50 years, with focal
segmental glomerulosclerosis. The primary outcome will be a
reduction in albumin excretion rate after 6 weeks of treatment.
Finally, another DARA has been developed by Torrent Pharmaceu-
ticals, termed TRC120038, a modiﬁed biphenylsulfonamide, with
an in vitro EC50 of 3 nM and 158 nM for human AT1 and ETA
receptors, respectively. Studies in ob-ZSF1 rats showed a greater
reduction in mean BP with TRC120038 than with candesartan, as
well as reduced renal dysfunction and improved cardiac function.
In summary, DARAs are in the early phases of study. Preclinical
trials and early clinical trials suggest that this new class of drugs
may be well tolerated and could be efﬁcacious in treating cardio-
renal diseases where targeting both ETA and AT1 would likely be
beneﬁcial.
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Background: AT1 antagonists like irbesartan and valsartan (IRB,
VAL) and an ETA antagonist like BMS-193884 (BMS) share a core
biphenyl structure. We tested the hypothesis that hybrids of these
compounds act as dual ETA/AT1 receptor antagonists (DARA).
Methods: We compared effects of IRB, VAL and BMS with those of
structural chimeras of IRB and BMS (PS-433540, DARA1) and of VAL
and BMS (ACT-214145, DARA2), all synthesized at Actelion (CH).
Contractile responses to angiotensin II (AngII) and endothelins (ET-1
and ET-2) were investigated in isolated rat mesenteric resistance
arteries where ETB-agonists and -antagonists have no effects.
Results: Presence of IRB, VAL, DARA1 and DARA2 reduced the
sensitivity and maximal responses to AngII-induced contraction with
comparable apparent afﬁnity (pA2: 9.5, 9.3, 9.7 and 9.2) while 10 nM
BMS was not effective. Presence of IRB (≤3 nM) or Val (≤100 nM) did
not modify responses to ET-1 (1–16 nM). BMS (1–30 nM), on the other
hand, potently reduced the sensitivity to ET-1 and ET-2 to the same
extent (pA2: 9.2 and 9.2). Notably, this effect of BMS displayed
saturability. It did not increase with increasing concentration in the
supra-nanomolar range and this was more marked against ET-1 than
against ET-2. The antagonistic effect of 10 nM BMS was signiﬁcantly
additive with that of the butenolide ETA-antagonist PD156707 (100 nM)
but not of the cyclic pentapeptide ETA-antagonist BQ123 (1 μM).
Furthermore, relaxing effects of 10 nM BMS on contractions induced by
16 nMET-1 or ET-2 (−57± 11 and−96± 3%)were signiﬁcantly larger
than those predicted by the effect of BMS on the sensitivity to the
peptides (−20± 10 and −19± 7%). These relaxing effects faded
rapidly upon washout of both the agonist and antagonist. Finally and in
sharp contrast to reported ﬁndings on radioligand–receptor binding and
on pressor responses induced by big ET-1 in vivo, both DARA1 and
DARA2 were ≥2.510 Log units less effective in reducing rat mesenteric
artery sensitivity to ET-1 and ET-2 than their commonBMS core structure
(pA2: 6.4, 6.2 and 9.2 against ET-1 and 6.8, 6.2 and 9.2 against ET-2).
Conclusion: The good news is that the biphenyl sulfonamide BMS is
a negative allosteric modulator of arterial smoothmuscle ETA receptors
which unlike BQ123 and PD156707 acts most effectively on agonist-
occupied activated receptors. The bad news is that the structure cannot
be expended with an AT1-receptor antagonistic part without profound
loss of afﬁnity for ETA at the tissue level. Also, the results suggest that
several allosteric modulatory sites may be present on ETA receptors.
This research was performed within the frame of TIPharma
project T2-301.
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